Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Roivant Sciences Ltd. (Nasdaq: ROIV) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Bermuda-incorporated biopharmaceutical issuer with common shares listed on The Nasdaq Global Select Market, Roivant files annual reports, quarterly updates, current reports on Form 8-K, proxy statements and other disclosures that describe its business, governance, financial condition and material events.
Through Roivant’s filings, investors can review detailed information on its biopharmaceutical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as the activities of subsidiaries such as Priovant Therapeutics, Immunovant, Pulmovant and Genevant. Current reports on Form 8-K have been used to furnish press releases on quarterly financial results, to report positive Phase 3 VALOR data in dermatomyositis, to provide updates on Graves’ disease development at Immunovant, and to disclose authorization of common share repurchase programs.
Roivant’s periodic reports discuss consolidated research and development and general and administrative expenses, share-based compensation, gains and losses from transactions such as the sale of Telavant net assets and the sale of its equity interest in Dermavant, and income or loss from discontinued operations. The company’s definitive proxy statement on Schedule 14A describes its annual general meeting of shareholders, director elections, auditor ratification and advisory votes on executive compensation, and lays out governance and compensation policies.
On Stock Titan, Roivant filings are paired with AI-powered summaries designed to help readers interpret complex documents. Users can quickly see the key points from 10-K and 10-Q reports, understand the significance of 8-K disclosures, and locate information related to capital allocation, clinical programs and subsidiary activities. Form 4 and other ownership-related filings, when available, can be used to track insider transactions and equity incentives disclosed by the company.
Roivant Sciences Ltd. director Oren Ilan reported compensation-related share movements. He received an award of 896 Common Shares under the company’s Non-Employee Director Compensation Plan, which was fully vested on the grant date. To cover tax withholding obligations on previously granted shares that vested and settled, 95 Common Shares were withheld and settled on a net basis by the company. Following these transactions, Ilan directly holds 120,324 Common Shares.
Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 670 Common Shares as equity compensation. The award was made under the company’s Non-Employee Director Compensation Plan and was fully vested on the grant date. Following this grant, she directly holds 16,474 Common Shares.
Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. He received 469 Common Shares as an award under Roivant’s Non-Employee Director Compensation Plan, which were fully vested on the grant date. To cover related tax withholding obligations, 94 previously granted Common Shares were net-settled back to the company. After these transactions, he directly holds 109,499 Common Shares. These entries reflect compensation and tax withholding mechanics rather than open-market buying or selling.
Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share. According to the filing, the trades occurred across multiple transactions between $28.98 and $29.36. After these sales, he directly owns 16,736,116 common shares.
Roivant Sciences Ltd. reported a Form 144 notice for the proposed sale of 200,000 common shares to be sold on 04/20/2026 (method: Options Exercise, grant date 04/20/2022). The filing also shows recent dispositions: 200,000 shares on 02/13/2026, 7,051 shares on 02/20/2026, and 200,000 shares on 04/20/2026, with proceeds listed for each transaction.
Rockefeller Financial LLC submitted an amended Form 144 (144/A) reporting proposed or previously executed sales of common stock of ROIV. The filing lists grant‑related securities (a CVAR grant and RSU grant) with grant dates and sale activity dated 03/30/2026 and 03/31/2026.
Rockefeller Financial LLC and related parties reported proposed and recent sales of Common Stock. The excerpt lists proposed dispositions of 43,493 shares (CVAR grant, dated 03/30/2026) and 246,281 RSUs (grant dated 07/26/2024) with settlement dates in late March 2026. It also reports sales by Matthew Gline on 03/30/2026 of 53,826 shares for $1,421,544.66 and 304,684 shares for $8,439,746.80.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported an open-market sale of 13,538 Common Shares of Roivant Sciences on April 8, 2026. The weighted average sale price was $28.37 per share, with individual trades executed between $28.36 and $28.38. After this transaction, she directly holds 84,191 Common Shares.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 160,035 common shares withheld on March 31, 2026 to cover tax obligations tied to previously granted RSUs. The issuer net settled these RSUs to satisfy applicable tax withholding, and Torti now directly holds 13,576,512 common shares.